Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 426 - 450 of 15247 in total

Thonzonium

Thonzonium is a monocationic surface-active agent with surfactant and detergent properties. It is widely used as an additive to in ear and nasal drops to enhance dispersion and penetration of cellular debris and exudate, thereby promoting tissue contact of the administered medication. A common pharmaceutical formulation of thonzonium bromide is...
Approved
Matched Iupac: … hexadecyl(2-{[(4-methoxyphenyl)methyl](pyrimidin-2-yl)amino}ethyl)dimethylazanium …
Matched Description: … It is widely used as an additive to in ear and nasal drops to enhance dispersion and penetration of cellular ... Thonzonium is a monocationic surface-active agent with surfactant and detergent properties. ... A common pharmaceutical formulation of thonzonium bromide is cortisporin-TC ear drops. …

Gilteritinib

Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other...
Approved
Investigational
Matched Iupac: … 6-ethyl-3-({3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-[(oxan-4-yl)amino]pyrazine …
Matched Description: … -driven myelosuppression observed in other therapies. ... [A40044] Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. ... Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors …

Omaveloxolone

Omaveloxolone (RTA-408) is a semisynthetic oleanane triterpenoid with antioxidant and anti-inflammatory properties.[A257534,A257539] Omaveloxolone acts as an activator of nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a transcription factor that mitigates oxidative stress. In patients with Friedreich's ataxia, a genetic disease involving mitochondrial dysfunction, the Nrf2 pathway is impaired, and Nrf2 activity...
Approved
Investigational
Matched Description: … [A257529] In February 2023, omaveloxolone was approved by the FDA for the treatment of Friedreich's ataxia ... In patients with Friedreich's ataxia, a genetic disease involving mitochondrial dysfunction, the Nrf2 ... Therefore, the use of Nrf2 activators such as omaveloxolone represents a therapeutic advantage in this …

Amaranthus retroflexus whole

Amaranthus retroflexus whole allergenic extract is used in allergenic testing.
Approved
Matched Description: … Amaranthus retroflexus whole allergenic extract is used in allergenic testing. …

Alternaria alternata

Alternaria alternata is a fungus which can provoke allergic reactions. Alternaria alternata extract is used in allergenic testing.
Approved
Matched Description: … Alternaria alternata extract is used in allergenic testing. ... Alternaria alternata is a fungus which can provoke allergic reactions. …
Matched Mixtures name: … Mold Mix A ... Mold Mix A ... Molds - Mold Mix 4 …

Naproxen

Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its...
Approved
Vet approved
Matched Description: … prescription use in 1976 and then for over-the-counter (OTC) use in 1994. ... for a variety of clinical situations requiring analgesia. ... [A179098] Naproxen is available in both immediate and delayed release formulations, in combination with …
Matched Products: … NEO EBLIMON ... A-NOX FORT 550 MG TABLET, 20 ADET ... NAPROXENO 2.5% POLVO PARA RECONSTITUIR A SUSPENSIÒN ORAL …

Crizotinib

Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers...
Approved
Investigational
Matched Iupac: … 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]pyridin-2-amine …
Matched Description: … [L42460] By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, ... [A250785] Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests ... Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase …
Matched Categories: … P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index …

Pamidronic acid

Pamidronic acid is a second generation, nitrogen containing bisphosphonate similar to neridronic acid and alendronic acid. Pamidronic acid was first described in the literature in 1977. The second generation bisphosphonates are less common as third generation bisphosphonates, such as ibandronic acid, zoledronic acid, minodronic acid, and risedronic acid are becoming...
Approved
Matched Description: … [A203111] Pamidronic acid was first described in the literature in 1977. ... Pamidronic acid is a second generation, nitrogen containing bisphosphonate similar to [neridronic acid …
Matched Products: … MENEDRON-L 15 MG IV ENJEKSİYONLUK LİYOFİLİZE TOZ İÇEREN FLAKON (4 FLAKON) …

Ripretinib

Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as sunitinib and imatinib. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020....
Approved
Matched Iupac: … 1-{4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl}-3-phenylurea …
Matched Description: … [L13769] It is the first drug approved as a fourth-line therapy in the specific setting of prior ... by the FDA on May 15, 2020. ... treatment with a minimum of 3 other kinase inhibitors. …

Diamorphine

Diamorphine (heroin) is a narcotic analgesic that may be habit-forming. It is a controlled substance (opium derivative) listed in the U.S. Code of Federal Regulations, Title 21 Parts 329.1, 1308.11 (1987). Sale is forbidden in the United States by Federal statute. (Merck Index, 11th ed) Internationally, diamorphine is controlled under...
Approved
Illicit
Investigational
Matched Iupac: … (1S,5R,13R,14S,17R)-10-(acetyloxy)-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca …
Matched Description: … Sale is forbidden in the United States by Federal statute. ... It is a controlled substance (opium derivative) listed in the U.S. ... However, under the name diamorphine, heroin is a legal prescription drug in the United Kingdom. …
Matched Categories: … Heterocyclic Compounds with 4 or More Rings ... Drugs Used in Opioid Dependence ... Drugs Used in Addictive Disorders …

Oxygen

Oxygen is an element displayed by the symbol O, and atomic number 8. It is an essential element for human survival. Decreased oxygen levels may be treated with medical oxygen therapy. Treatment with oxygen serves to increase blood oxygen levels and also exerts a secondary effect of decreasing blood flow...
Approved
Vet approved
Matched Description: … Oxygen is an element displayed by the symbol O, and atomic number 8. ... blood flow resistance in the diseased lung, leading to decreased cardiovascular workload in an attempt ... Treatment with oxygen serves to increase blood oxygen levels and also exerts a secondary effect of decreasing …
Matched Mixtures name: … Oxygen In Helium Mix ... Nitrous Oxide In Oxygen ... Oxygen In Helium Mixture …
Matched Products: … N/A …

Ergocalciferol

Ergocalciferol is an inactivated vitamin D analog. It is synthesized by some plants in the presence of UVB light. The production of ergocalciferol was prompted by the identification of dietary deficiency, more specifically vitamin D, as the main causative factor for the development of rickets. Ergocalciferol was isolated for the...
Approved
Nutraceutical
Matched Iupac: … ylidene]ethylidene}-4-methylidenecyclohexan-1-ol ... 1S,3Z)-3-{2-[(1R,3aS,4E,7aR)-1-[(2R,3E,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-octahydro-1H-inden-4- …
Matched Description: … [A177526] It is synthesized by some plants in the presence of UVB light. ... the presence of a double bond between C22 and C23 and the presence of a methyl group at C24. ... Ergocalciferol was isolated for the first time from yeast in 1931 and its structure was elucidated in …
Matched Mixtures name: … Mvc 9+4 Inj ... One A Day Tab ... Aquasol A & D Drops …

Famtozinameran

The Omicron variant of SARS-CoV-2 is a variant of concern that was first reported in November 2021. It tends to cause less severe disease but is significantly more virulent than both the original virus and earlier variants (e.g. Delta). As of November 2022, it is the primary circulating variant of...
Approved
Investigational
Matched Description: … by SARS-CoV-2, including infection caused by Omicron BA.4/BA.5. ... The Omicron variant of SARS-CoV-2 is a variant of concern that was first reported in November 2021. ... It is administered in combination with [tozinameran] for active immunization against COVID-19 caused …
Matched Mixtures name: … Comirnaty Original & Omicron Ba.4/ba.5 ... Comirnaty Original & Omicron Ba.4/ba.5 ... Comirnaty Original & Omicron Ba.4/ba.5 …

Ketoconazole

Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections.[FDA Label] It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus.[A181802,T116] Ketoconazole was first approved in an oral formulation...
Approved
Investigational
Matched Iupac: … 1-[4-(4-{[2-(2,4-dichlorophenyl)-2-[(1H-imidazol-1-yl)methyl]-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin …
Matched Description: … [A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in ... Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal ... [A188054] At this time it was considered a significant improvement over previous antifungals, [miconazole …
Matched Mixtures name: … Ketoconazole 2% / Niacinamide 4% …
Matched Products: … Nizoral A-D ... A-BE LOTION …

Gluconic Acid

Commonly found in salts with sodium and calcium. Gluconic acid or gluconate is used to maintain the cation-anion balance on electrolyte solutions.
Approved
Investigational
Matched Description: … Commonly found in salts with sodium and calcium. …
Matched Mixtures name: … Plasma-Lyte A ... Isolyte S in Dextrose ... PLASMA-LYTE A INJECTION …

Dabrafenib

Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib),...
Approved
Investigational
Matched Iupac: … N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzene-1- …
Matched Description: … to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene. ... [L41955] In May 2018, Tafinlar (dabrafenib), in combination with Mekinist ([DB08911]), was approved ... Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK …
Matched Categories: … P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …

Vildagliptin

Vildagliptin (LAF237) is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. It is used to manage type II diabetes mellitus, where GLP-1 secretion and insulinotropic effects are impaired. By inhibiting DPP-4, vildagliptin prevents the degradation of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP),...
Approved
Investigational
Matched Description: … [A232488] By inhibiting DPP-4, vildagliptin prevents the degradation of glucagon-like peptide 1 (GLP- ... [A232488] Oral vildagliptin was approved by the European Medicines Agency in 2008 for the treatment ... of type II diabetes mellitus in adults as monotherapy or in combination with [metformin], a sulfonylurea …
Matched Categories: … Drugs Used in Diabetes …

Armodafinil

Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists...
Approved
Investigational
Matched Description: … (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. ... Armodafinil is produced by the pharmaceutical company Cephalon Inc. ... Food and Drug Administration (FDA) in June 2007. …

Brigatinib

Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a...
Approved
Investigational
Matched Iupac: … 5-chloro-N4-[2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl] …
Matched Description: … , which is a pivotal player in the transformation of susceptible lung parenchyma. ... [A31313] Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company ... It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene …
Matched Categories: … Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …

Sodium acetate

Sodium Acetate is chemically designated CH3COONa, a hygroscopic powder very soluble in water. Sodium acetate could be used as additives in food, industry, concrete manufacture, heating pads and in buffer solutions. Medically, sodium acetate is important component as an electrolyte replenisher when given intravenously. It is mainly indicated to correct...
Approved
Investigational
Matched Description: … Sodium Acetate is chemically designated CH3COONa, a hygroscopic powder very soluble in water. ... Sodium acetate could be used as additives in food, industry, concrete manufacture, heating pads and in ... It can be used also in metabolic acidosis and for urine alkalinization. …
Matched Salts cas: … 6131-90-4 …
Matched Mixtures name: … GELOFUSINE® ISO 4% ... Plasma-Lyte A ... PLASMA-LYTE A INJECTION …

Lithium citrate

Approved

Latanoprost

Latanoprost is a prodrug analog of prostaglandin F2 alpha that is used to treat elevated intraocular pressure (IOP). It was initially approved by the FDA in 1998. Latanoprost is the first topical prostaglandin F2 alpha analog used for glaucoma treatment. It has been found to be well-tolerated and its use...
Approved
Investigational
Matched Description: … It was initially approved by the FDA in 1998. ... Another benefit latanoprost is that it can be administered once a day.[A184490] ... Latanoprost is a prodrug analog of prostaglandin F2 alpha that is used to treat elevated intraocular …
Matched Categories: … Compounds used in a research, industrial, or household setting …

Brexucabtagene autoleucel

Mantle cell lymphoma is a heterogeneous sub-category of non-Hodgkin's lymphoma that can be classified as either an aggressive nodal or an indolent leukemic non-nodal variant. Despite the introduction of Bruton's tyrosine kinase (BTK) inhibitors such as ibrutinib and acalabrutinib, the prognosis for MCL patients remains poor and those that relapse...
Approved
Matched Description: … Brexucabtagene autoleucel was granted accelerated approval for the treatment of relapsed and refractory MCL by ... method of T cell enrichment that decreases the prevalence of CD19-expressing tumour cells in the CAR ... These therapies differ in manufacturing methodology, viral vector, chimeric antigen choice, and the internal …
Matched Categories: … Antineoplastic cell and gene therapy …

Liotrix

Liotrix is a synthetically derived thyroid hormone replacement preparation. It consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in a 4 to 1 ratio by weight. Liotrix was developed when it was believed that serum levels of both T4 and T3 were maintained by direct thyroidal secretion....
Approved
Matched Iupac: … 4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoate ... disodium (2S)-2-amino-3-[4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl]propanoate (2S)-2-amino-3-[ …
Matched Description: … a 4 to 1 ratio by weight. ... Liotrix is a synthetically derived thyroid hormone replacement preparation. ... Liotrix was developed when it was believed that serum levels of both T4 and T3 were maintained by direct …

Padeliporfin

Padeliporfin is a water-soluble chlorophyll derivative and cytotoxic photosensitizer used for vascular-targeted photodynamic therapy for malignancies. Vascular-targeted photodynamic therapy (VTP), or vascular targeted photochemotherapy, is a focal treatment for localized prostate cancer. It aims to destroy only cancerous lesions of the prostate, rather than ablating the entire prostate gland. Padeliporfin...
Approved
Experimental
Matched Iupac: … palladium(2+) (4S,5S,14R,15R)-10-acetyl-4-(2-carboxyethyl)-15-ethyl-2-(2-methoxy-2-oxoethyl)-5,9,14,19 …
Matched Description: … of low-risk prostate cancer in adults meeting certain clinical criteria. ... [A244699] Padeliporfin was first approved by the European Commission on November 10, 2017, for the treatment ... [A244559] Vascular-targeted photodynamic therapy (VTP), or vascular targeted photochemotherapy, is a …
Matched Categories: … Heterocyclic Compounds with 4 or More Rings ... Sensitizers Used in Photodynamic/radiation Therapy …
Displaying drugs 426 - 450 of 15247 in total